Algert Global LLC Chinook Therapeutics, Inc. Transaction History

Algert Global LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$18.66 - $38.58 $1.17 Million - $2.43 Million	-62,910 Reduced 46.15%	73,406 $2.82 Million
Q1 2023 May 12, 2023	BUY	$21.53 - $26.8 $105,260 - $131,025	4,889 Added 3.72%	136,316 $3.16 Million
Q4 2022 Feb 13, 2023	SELL	$18.63 - $27.35 $26,640 - $39,110	-1,430 Reduced 1.08%	131,427 $3.44 Million
Q3 2022 Nov 15, 2022	BUY	$17.51 - $23.37 $2.01 Million - $2.68 Million	114,537 Added 625.2%	132,857 $2.61 Million
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $230,648 - $344,416	18,320 New	18,320 $320,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.